Alseres Pharmaceuticals Inc represents values of innovation, dedication, and excellence in the pharmaceutical industry. The company's corporate philosophy focuses on developing and commercializing breakthrough therapies to address unmet medical needs. Alseres Pharmaceuticals Inc is committed to enhancing patient outcomes by delivering cutting-edge treatments and advancing medical science. With a strong emphasis on research and development, the company strives to bring novel therapeutic options to market, improving the quality of life for patients worldwide. Alseres Pharmaceuticals Inc's mission is to harness the potential of science and technology to transform healthcare and make a positive impact on global health.

Alseres Pharmaceuticals Inc, a renowned pharmaceutical company, primarily operates in the United States. With headquarters located in Massachusetts, Alseres Pharmaceuticals focuses on the development and commercialization of innovative diagnostic and therapeutic products.

Alseres Pharmaceuticals Inc has achieved several significant milestones. The company successfully completed a Phase III clinical trial for their lead product, Altropane, which is used in the diagnosis of Parkinson's disease. Furthermore, they have received FDA approval as a New Drug Application for Altropane. Alseres Pharmaceuticals Inc has also secured partnerships and collaborations with prominent organizations in the healthcare industry. Their dedication to innovation and commitment to improving patient outcomes have positioned them as a leader in the pharmaceutical sector.

Alseres Pharmaceuticals Inc., founded in 1992, is a biotechnology company dedicated to developing innovative therapeutic and diagnostic products for various neurological disorders. With a robust history and background, Alseres has been at the forefront of medical advancements. The company initially focused on magnetic resonance imaging (MRI) enhancing agents and later expanded into the development of treatments for ischemic stroke and traumatic brain injury. Alseres Pharmaceuticals Inc. strives to address unmet medical needs, leveraging scientific expertise and strategic partnerships to bring transformative solutions to patients worldwide. With a proven track record and commitment to improving patient outcomes, Alseres Pharmaceuticals Inc. continues to shape the future of neurological therapeutics.

The main competitors of Alseres Pharmaceuticals Inc in the market include companies such as Pfizer, Merck & Co., Novartis AG, and Johnson & Johnson.

Alseres Pharmaceuticals Inc is primarily active in the biotechnology industry.

The business model of Alseres Pharmaceuticals Inc revolves around developing and commercializing innovative therapeutic products primarily for the treatment of neurodegenerative disorders. Alseres focuses on utilizing its proprietary technologies and expertise in targeted therapies to provide novel solutions for patients suffering from diseases like Parkinson's and ischemic stroke. By leveraging strategic partnerships and collaborations, Alseres aims to advance its drug candidates through clinical development stages and ultimately gain regulatory approvals for commercialization. This business model emphasizes Alseres' commitment to utilizing cutting-edge research and development to address critical unmet medical needs in the field of neurology.

Současně nelze vypočítat KGV pro Alseres Pharmaceuticals.

KUV pro Alseres Pharmaceuticals nelze v současné době vypočítat.

AlleAktien kvalitní skóre pro Alseres Pharmaceuticals je 2/10.

Tržby pro Alseres Pharmaceuticals nelze v současné době vypočítat.

Zisk pro Alseres Pharmaceuticals nelze v současnosti vypočítat.

Alseres Pharmaceuticals Inc is a biopharmaceutical company specialized in the development and commercialization of therapeutics and diagnostics for the treatment of neurological diseases. The company was founded in 1992 and is headquartered in Hopkinton, Massachusetts. Alseres Pharmaceuticals Inc's business activities are divided into three segments: diagnostics, therapeutics, and pharmaceutical services. The company's diagnostics segment specializes in the development and commercialization of molecular imaging techniques. Products in this segment include a wide range of radioactive tracers used in conjunction with imaging techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) to measure and visualize brain and organ activity. Current products in the diagnostics segment include Altropane, a SPECT imaging agent for the diagnosis of Parkinson's disease, and Datscan, used for the diagnosis of movement disorders. In the therapeutics segment, Alseres Pharmaceuticals focuses on the development and commercialization of therapies for the treatment of neurological diseases. The main product in this segment is currently Cethrin, a treatment for spinal cord injuries. Cethrin is a synthetic protein that promotes axonal regeneration by binding to glycosaminoglycans in the extracellular matrix. The drug is considered a promising therapy for spinal cord injuries and other neurological disorders due to its neuroprotective and neuroregenerative properties. Alseres Pharmaceuticals also provides pharmaceutical services including manufacturing, distribution, and marketing of therapeutic and diagnostic products. The company also offers customized solutions for customers in the biotechnology, pharmaceutical, and medical device industries. The future of Alseres Pharmaceuticals relies on the successful development and commercialization of drugs and diagnostics for the treatment of neurological diseases. To achieve this goal, the company has entered into a number of partnership and licensing agreements with leading pharmaceutical companies such as Pfizer and Genzyme Corp. These agreements allow Alseres to secure access to resources and expertise and accelerate the development and commercialization of products. In summary, Alseres Pharmaceuticals is a biopharmaceutical company specialized in neurological diseases, offering a wide range of products and services. Through the continuous development and commercialization of innovative therapeutics and diagnostics, the company aims to improve the quality of life for patients with neurological disorders. In a dynamic industry, the future of Alseres Pharmaceuticals is promising as the company continues to develop new therapeutic approaches and diagnostic technologies to meet the needs of patients. Answer: Alseres Pharmaceuticals Inc is a biopharmaceutical company specialized in the development and commercialization of therapeutics and diagnostics for neurological diseases.

Alseres Pharmaceuticals vyplácí dividendu ve výši 0 USD rozdělenou do výplat během roku.

Dividenda pro Alseres Pharmaceuticals momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Alseres Pharmaceuticals je US0211522026.

WKN společnosti Alseres Pharmaceuticals je A12HL8.

Ticker společnosti Alseres Pharmaceuticals je ALSE.

Během posledních 12 měsíců vyplatila společnost Alseres Pharmaceuticals dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Alseres Pharmaceuticals vyplatí dividendu ve výši 0 USD.

Výnos z dividend společnosti Alseres Pharmaceuticals aktuálně činí .

Alseres Pharmaceuticals vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Alseres Pharmaceuticals vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 USD. To odpovídá dividendovému výnosu 0 %.

Alseres Pharmaceuticals je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Alseres Pharmaceuticals ve výši 0 USD, zaznamenané 30. 9. 2025, měl jsi mít akcii ve svém portfoliu před ex-dnem 30. 9. 2025.

Poslední dividendy byly vyplaceny dne 30. 9. 2025.

V roce 2024 společností Alseres Pharmaceuticals bylo vyplaceno 0 USD ve formě dividend.

Dividendy společnosti Alseres Pharmaceuticals jsou vypláceny v USD.